Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy

Overview

The purpose of this study is to compare the efficacy and safety of intravitreal Aflibercept monotherapy with the efficacy and safety of combined treatment with Aflibercept plus standard photodynamic therapy (PDT) with Verteporfin in age-related macular degeneration (AMD) patients with polypoidal choroidal vasculopathy (PCV).

Full Title of Study: “A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of IV Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With PCV.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: August 22, 2017

Detailed Description

To compare the efficacy and safety of intravitreal Aflibercept monotherapy with the efficacy and safety of combined treatment with Aflibercept associated with standard photodynamic therapy (PDT) with Verteporfin in age-related macular degeneration (AMD) patients with polypoidal choroidal vasculopathy (PCV) in a proof concept study and to identify genetic biomarkers for the diagnosis and treatment response of PCV in Caucasians.

Interventions

  • Drug: Intravitreal Aflibercept

Arms, Groups and Cohorts

  • Sham Comparator: Aflibercept Monotherapy
    • IVT Aflibercept 2 mg + Sham PDT
  • Active Comparator: Aflibercept + verteporfin PDT
    • IVT Aflibercept 2 mg + Verteporfin PDT

Clinical Trial Outcome Measures

Primary Measures

  • Change in Best Corrected Visual Acuity (BCVA)
    • Time Frame: from Baseline (Week 0) to Week 52.
    • Unit of Measure: [Letters]
  • Polyps regression
    • Time Frame: from Baseline (W0) to Week 52.
    • Unit of Measure: [Yes, No]

Secondary Measures

  • Polyps regression, assessed by Indocyanine Green Angiography (ICGA);
    • Time Frame: from Baseline (W0) to Week 16
    • Unit of Measure: [Yes, No]
  • Presence of active polyps, assessed by Indocyanine Green Angiography (ICGA);
    • Time Frame: from Baseline (W0) to Week 52
    • Unit of Measure: [Yes, No]
  • Presence of leakage based on fluorescein angiography (FA)
    • Time Frame: from Baseline (W0) to Week 52
    • Unit of Measure: [Yes, No]
  • Change in the Subfield Central Retinal Thickness (CRT), assessed by Spectral Domain-Optical Coherence Tomography (SD-OCT);
    • Time Frame: from Baseline (W0) to Week 52
    • Unit of Measure: [µm]
  • Presence of fluid assessed on Spectral Domain-Optical Coherence Tomography (SD-OCT) at Week 52;
    • Time Frame: from Baseline (W0) to Week 52
    • Unit of Measure: [Yes, No]
  • Total number of treatments with Aflibercept;
    • Time Frame: from Baseline (W0) to Week 52
    • Unit of Measure: [#]
  • Frequency and severity of ocular and non-ocular adverse events over time.
    • Time Frame: from Baseline (W0) to Week 52
    • Unit of Measure: [Mild, Moderate, Severe]

Participating in This Clinical Trial

Inclusion Criteria

  • Either gender and Age ≥ 50. – Naïve PCV patients. – Confirmed diagnosis of symptomatic macular PCV in the study eye. – Greatest linear dimension of the lesion of < 5400 mm, assessed by ICG angiography. – BCVA at study entry of 25 to 80 letters (Snellen Equivalent 20/320 to 20/25). – Lesion size in the study eye at study entry: – Presence of PCV assessed by the Central Reading Centre based on ICG with active polyps with or without abnormal vascular network. – Women must be using effective contraception, be post-menopausal for at least – months prior to trial entry, or surgically sterile. – Ability to provide written informed consent. – Ability to return for all study visits. Exclusion Criteria:

  • Active inflammation or infection in the study eye. – Uncontrolled intraocular pressure in the study eye. – Ocular condition in the study eye which may impact vision and confound study outcomes (e.g. vitreomacular traction, epirretinal membrane with BCVA impact, ocular inflammation, retinal vascular diseases like diabetic retinopathy or diabetic macular edema). – Presence of centromacular scarring or atrophy indicating irreversible BCVA loss. – Prior treatment of the study eye with anti-VEGF therapy or systemic use of anti-VEGF products within 3 months prior to the study entry. – Previous vitrectomy, macular laser treatment, PDT, or intraocular steroids in the study eye.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Association for Innovation and Biomedical Research on Light and Image
  • Collaborator
    • European Vision Institute Clinical Research Network
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Rufino Silva, PhD, Principal Investigator, Association for Innovation and Biomedical Research on Light and Image

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.